Journals / Genel Tıp Dergisi / 1997 / Cilt: 7 - Sayı: 2

Fucose and fucosidase in gastrointestinal malignancies

Gastrointestinal malignitelerde fukoz ve fukozidaz

Pages
89–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings may be a stimulus for further research of fucose metabolism in malignancy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Recently, protein bound carbohydrates have been investigated as indexes of glycoprotein levels in cancer.
📊
Key Findings & Data:Methods: In the control (n=20), cirrhotic (n=20) and gastrointestinal malignancy (n=20) groups, protein bound fucose (PBF) was determined by the Dische and Shettles technique.
💡
Conclusion & Impact:These findings may be a stimulus for further research of fucose metabolism in malignancy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Recently, protein bound carbohydrates have been investigated as indexes of glycoprotein levels in cancer. This study investigates the changes in L-fucose, and its enzyme a-L-fucosidase in gastrointestinal malignancies. Methods: In the control (n=20), cirrhotic (n=20) and gastrointestinal malignancy (n=20) groups, protein bound fucose (PBF) was determined by the Dische and Shettles technique. For its M fraction, the Tatsumura extraction procedure was applied. The G fraction was estimated by subtracting M from total. a-L-fucosidase was estimated as nanomoles of p-nitrophenyl a-L-fucoside, cleaved per ml of serum, per hour at 37 oC. Results: PBF was 7.33±1.36, 13.16±2.88 and 14.53±3.25 mg/dl, a-L-fucosidase was 319.2±99.5, 463.6±215.9 and 528.5±347.3 nmol/ml/h in the control, cirrhotic and malignant groups, respectively. Total fucose, its G and M fractions, fucose/protein ratio and a-L-fucosidase were significantly higher in the malignant group compared to the controls (for the fucosidase p<0.02, for the others p<0.001). However, in the malignant group compared to the cirrhotics, only the total fucose/protein ratio was significantly higher (p<0.05). Satisfactory results (all above 70% ) related to sensitivity, specificity and diagnostic accuracy were also obtained. Conclusion: We conclude that a-L-fucosidase and especially fucose are promising tumor markers in establishing gastrointestinal malignancies. These findings may be a stimulus for further research of fucose metabolism in malignancy.

Özet

Amaç: Serum glikoproteinlerindeki değişimler malignitelerde karakteristiktir. Son zamanlarda protein bağlı karbonhidratlar kanserde glikoprotein seviyesinin bir göstergesi olarak incelenmektedir. Bu çalışmada, gastrointestinal malignitelerde, L-fukoz ile onun enzimi a-L-fukozidaz’daki değişimleri incelemek amaçlanmıştır. Yöntem: Kontrol (n=20), siroz (n=20) ve gastrointestinal malignite (n=20) gruplarının Proteine bağlı fukoz (PBF) değerleri Dische ve Shettles’in yöntemiyle tayin edildi. M fraksiyonu için Tatsumura’nın ekstraksiyon yöntemi uygulandı. G fraksiyonu totalden M çıkarılarak hesaplandı. a-L-fukozidaz aktivitesi 37 oC’de 1 saatte parçalanan p-nitrofenil a-L-fukozid’in 1 ml’de nanomol cinsinden miktarı şeklinde belirlendi. Total protein biüret yöntemiyle ölçüldü. Bulgular: PBF değerleri kontrol, siroz ve malignite gruplarında sırasıyla 7.33±1.36, 13.16±2.88 ve 14.53±3.25 mg/dl; a-L-fukozidaz değerleri 319.2±99.5, 463.6±215.9 ve 528.5±347.3 nmol/ml/saat idi. Total fukoz, G ve M fraksiyonları, fukoz/protein oranı ve a-L-fukozidaz malign grupta, kontrol grubuna göre anlamlı şekilde yüksekti (fukozidaz için p<0.02, diğerleri için p<0.001). Fakat malign-siroz karşılaştırmasında yalnız total fukoz/protein oranı anlamlı şekilde yüksekti (p<0.05). Sensitivite, spesifite ve teşhis doğruluğu yönünden (% 70’in üzerinde) olumlu sonuçlar elde edildi. Sonuç: a-L-fukozidaz ve özellikle fukozun gastrointestinal malignitelerde ümit vaat eden tümör belirteçleri olduğunu tesbit ettik. Bu bulgular malignitede fukoz metabolizmasının daha ileri araştırılması yönünde teşvik edicidir

🔖

Cite This Article

ÇAĞLAYAN, O., ERSÖZ, B., MENTEŞ, G., OSMANOĞLU, N. (1997). Fucose and fucosidase in gastrointestinal malignancies. Genel Tıp Dergisi, Cilt: 7 - Sayı: 2, 89–93. https://ajindex.com/articles/225186

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Yogeeswaran G. Cell surface glycolipids and glycoproteins in malignant transformation. Adv Cancer Res 1983;38:289-350
  2. Bradley WP, Blasco AP, Weiss JF, Alexander JC, Silverman NA, Chretien PB. Correlations among serum protein bound carbohydrates, serum glycoproteins, lymphocyte reactivity and tumor burden in cancer patients. Cancer 1977;40:2264-72.
  3. Macbeth RAL, Bekesi JG. Plasma glycoproteins in various disease states including carcinoma. Cancer Res 1962;22:1170-6.
  4. Nigam VN, Cantero A. Polysaccharides in cancer: Glycoproteins and glycolipids. Adv Cancer Res 1973;17:1-80.
  5. Turner GA, Skillen AW, Buamah P, Guthrie D, Welsh J, Harrison J, et al. Relation between raised concentrations of fucose, sialic acid and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers. J Clin Pathol 1985;38:588-92.
  6. Bhuvarahamurthy V, Balasubramanian N, Vijayakumar S, Govindasamy S. Effect of radiation on serum glycoproteins and glycosidases in patients with cervical carcinoma. Int J Gynaecol Obstet 1995;48:49-54.
  7. Patel PS, Adhvaryu SG, Balar DB, Parikh BJ, Shah PM. Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumour markers in human leukemias. Anticancer Res 1994;14(2B):747-51.
  8. Jass JR, Allison LJ, Stewart SM, Lane MR. Ulex europaeus agglutinin-1 binding in hereditary bowel cancer. Pathology 1993;25:114-9.
  9. Barlow JJ, Dillard PH. Serum protein bound fucose in patients with gynecologic cancers. Obstet Gynecol 1972;39:727-34.
  10. Evans AS, Dolan MF, Sobocinski PZ, Quinn FA. Utility of serum protein bound neutral hexoses and L-fucose for estimation of malignant tumor extension and evaluation of efficacy of therapy. Cancer Res 1974;34:538-42.
  11. Hadjivassilou A, Castanaki A, Hristou G, Lissaios B. The diagnostic value of protein bound serum fucose in cancer of the brest. Surg Gynec Obst 1975;140:239-40. Klishevich IB. Serum albumin fucose in cancer patients. Vopr Onkol 1982;28:38-40.
  12. Marth E, Flaschka G, Stiegler S, Möse JR. Sialic acid as a marker for differentiation between benign and malignant intracranial tumors. Clin Chim Acta 1988;176:251-8.
  13. Rosato FE, Seltzer MH. Serum protein bound fucose and carcinoma of the female breast. Am J Surg 1969;118:61-4. Rosato FE. Serum glycoproteins in the evaluation of breast cancer. Surg Gynec Obst 1967;124:1291-4. Rosato FE. Glycoproteins in mammary cancer. Ann Surg 1968;168:818-20.
  14. Tatsumura T, Sato H, Mori A, Komori Y, Yamamoto K, Fukatani G, et al. Clinical signi